151. Recombinant Mycoplasma mycoides proteins elicit protective immune responses against contagious bovine pleuropneumonia.
- Author
-
Nkando, Isabel, Perez-Casal, Jose, Mwirigi, Martin, Prysliak, Tracy, Townsend, Hugh, Berberov, Emil, Kuria, Joseph, Mugambi, John, Soi, Reuben, Liljander, Anne, Jores, Joerg, Gerdts, Volker, Potter, Andrew, Naessens, Jan, and Wesonga, Hezron
- Subjects
- *
RECOMBINANT proteins , *MYCOPLASMA mycoides , *CONTAGIOUS bovine pleuropneumonia , *IMMUNE response , *RESPIRATORY diseases - Abstract
Mycoplasma mycoides subsp. mycoides ( Mmm ) is the causative agent of contagious bovine pleuropneumonia (CBPP), a devastating respiratory disease mainly affecting cattle in sub-Saharan Africa. The current vaccines are based on live-attenuated Mmm strains and present problems with temperature stability, duration of immunity and adverse reactions, thus new vaccines are needed to overcome these issues. We used a reverse vaccinology approach to identify 66 Mmm potential vaccine candidates. The selection and grouping of the antigens was based on the presence of specific antibodies in sera from CBPP-positive animals. The antigens were used to immunize male Boran cattle ( Bos indicus ) followed by a challenge with the Mmm strain Afadé. Two of the groups immunized with five proteins each showed protection after the Mmm challenge (Groups A and C; P < 0.05) and in one group (Group C) Mmm could not be cultured from lung specimens. A third group (Group N) showed a reduced number of animals with lesions and the cultures for Mmm were also negative. While immunization with some of the antigens conferred protection, others may have increased immune-related pathology. This is the first report that Mmm recombinant proteins have been successfully used to formulate a prototype vaccine and these results pave the way for the development of a novel commercial vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF